B cells are not required for T cell priming in low zone tolerance to contact allergens and contact hypersensitivity. 2004

Wolfgang Seidel-Guyenot, and Ruth Alt, and Sylwia Perschon, and Jürgen Knop, and Kerstin Steinbrink
Department of Dermatology, University of Mainz, Mainz, Germany.

Low zone tolerance (LZT) to contact allergens is induced by epicutaneous exposure to haptens in subsensitizing doses resulting in an inhibition of contact hypersensitivity (CHS), which, in contrast, occurs after sensitization with immunogenic doses of allergens. Performing the protocol of tolerance induction resulted in robust LZT to allergens in B cell-deficient mice in vivo, indicating that B cells are not required for the induction and effector phase of LZT. However, CHS reactions in vivo were restricted in B cell-deficient mice as compared to wild-type (WT) mice. In contrast, analysis of hapten-specific T cell activation in vitro revealed a strong proliferative response of T cells derived from both WT and B cell-deficient sensitized mice. Similar to WT animals, T cells obtained from tolerized B cell-deficient mice produced a Tc2 cytokine pattern of LZT with high levels of IL-4 and IL-10, whereas sensitization of B cell-deficient mice resulted in the typical Tc1 cytokine profile of CHS. Adoptive transfer of CD8+ effector T cells from tolerized or sensitized B cell-deficient mice induced significant LZT or CHS reactions, respectively, in WT recipients, demonstrating that the development of hapten-specific effector CD8+ T cells of LZT and CHS is independent of B cells.

UI MeSH Term Description Entries
D007108 Immune Tolerance The specific failure of a normally responsive individual to make an immune response to a known antigen. It results from previous contact with the antigen by an immunologically immature individual (fetus or neonate) or by an adult exposed to extreme high-dose or low-dose antigen, or by exposure to radiation, antimetabolites, antilymphocytic serum, etc. Immunosuppression (Physiology),Immunosuppressions (Physiology),Tolerance, Immune
D007371 Interferon-gamma The major interferon produced by mitogenically or antigenically stimulated LYMPHOCYTES. It is structurally different from TYPE I INTERFERON and its major activity is immunoregulation. It has been implicated in the expression of CLASS II HISTOCOMPATIBILITY ANTIGENS in cells that do not normally produce them, leading to AUTOIMMUNE DISEASES. Interferon Type II,Interferon, Immune,gamma-Interferon,Interferon, gamma,Type II Interferon,Immune Interferon,Interferon, Type II
D007378 Interleukins Soluble factors which stimulate growth-related activities of leukocytes as well as other cell types. They enhance cell proliferation and differentiation, DNA synthesis, secretion of other biologically active molecules and responses to immune and inflammatory stimuli. Interleukin
D008198 Lymph Nodes They are oval or bean shaped bodies (1 - 30 mm in diameter) located along the lymphatic system. Lymph Node,Node, Lymph,Nodes, Lymph
D008213 Lymphocyte Activation Morphologic alteration of small B LYMPHOCYTES or T LYMPHOCYTES in culture into large blast-like cells able to synthesize DNA and RNA and to divide mitotically. It is induced by INTERLEUKINS; MITOGENS such as PHYTOHEMAGGLUTININS, and by specific ANTIGENS. It may also occur in vivo as in GRAFT REJECTION. Blast Transformation,Blastogenesis,Lymphoblast Transformation,Lymphocyte Stimulation,Lymphocyte Transformation,Transformation, Blast,Transformation, Lymphoblast,Transformation, Lymphocyte,Activation, Lymphocyte,Stimulation, Lymphocyte
D008810 Mice, Inbred C57BL One of the first INBRED MOUSE STRAINS to be sequenced. This strain is commonly used as genetic background for transgenic mouse models. Refractory to many tumors, this strain is also preferred model for studying role of genetic variations in development of diseases. Mice, C57BL,Mouse, C57BL,Mouse, Inbred C57BL,C57BL Mice,C57BL Mice, Inbred,C57BL Mouse,C57BL Mouse, Inbred,Inbred C57BL Mice,Inbred C57BL Mouse
D010081 Oxazolone Immunologic adjuvant and sensitizing agent. 2-Phenyl-4-(ethoxymethylene)oxazol-5-one,4-Ethoxymethylene-2-phenyloxazolone,4 Ethoxymethylene 2 phenyloxazolone
D010853 Picryl Chloride A hapten that generates suppressor cells capable of down-regulating the efferent phase of trinitrophenol-specific contact hypersensitivity. (Arthritis Rheum 1991 Feb;34(2):180). 2,4,6-Trinitro-1-chlorobenzene,1-Chloro-2,4,6-trinitrobenzene,Trinitrochlorobenzene,Chloride, Picryl
D003877 Dermatitis, Contact A type of acute or chronic skin reaction in which sensitivity is manifested by reactivity to materials or substances coming in contact with the skin. It may involve allergic or non-allergic mechanisms. Contact Dermatitis,Dermatitis Venenata,Eczema, Contact,Hypersensitivity, Contact,Sensitivity, Contact,Contact Dermatitides,Contact Eczema,Contact Hypersensitivities,Contact Hypersensitivity,Contact Sensitivities,Contact Sensitivity,Dermatitides, Contact,Hypersensitivities, Contact,Sensitivities, Contact
D000276 Adjuvants, Immunologic Substances that augment, stimulate, activate, potentiate, or modulate the immune response at either the cellular or humoral level. The classical agents (Freund's adjuvant, BCG, Corynebacterium parvum, et al.) contain bacterial antigens. Some are endogenous (e.g., histamine, interferon, transfer factor, tuftsin, interleukin-1). Their mode of action is either non-specific, resulting in increased immune responsiveness to a wide variety of antigens, or antigen-specific, i.e., affecting a restricted type of immune response to a narrow group of antigens. The therapeutic efficacy of many biological response modifiers is related to their antigen-specific immunoadjuvanticity. Immunoactivators,Immunoadjuvant,Immunoadjuvants,Immunologic Adjuvant,Immunopotentiator,Immunopotentiators,Immunostimulant,Immunostimulants,Adjuvant, Immunologic,Adjuvants, Immunological,Immunologic Adjuvants,Immunological Adjuvant,Adjuvant, Immunological,Immunological Adjuvants

Related Publications

Wolfgang Seidel-Guyenot, and Ruth Alt, and Sylwia Perschon, and Jürgen Knop, and Kerstin Steinbrink
August 1996, The Journal of investigative dermatology,
Wolfgang Seidel-Guyenot, and Ruth Alt, and Sylwia Perschon, and Jürgen Knop, and Kerstin Steinbrink
March 1996, The Journal of experimental medicine,
Wolfgang Seidel-Guyenot, and Ruth Alt, and Sylwia Perschon, and Jürgen Knop, and Kerstin Steinbrink
January 1996, Proceedings of the National Academy of Sciences of the United States of America,
Wolfgang Seidel-Guyenot, and Ruth Alt, and Sylwia Perschon, and Jürgen Knop, and Kerstin Steinbrink
January 2001, Critical reviews in immunology,
Wolfgang Seidel-Guyenot, and Ruth Alt, and Sylwia Perschon, and Jürgen Knop, and Kerstin Steinbrink
March 2010, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons,
Wolfgang Seidel-Guyenot, and Ruth Alt, and Sylwia Perschon, and Jürgen Knop, and Kerstin Steinbrink
June 1994, The Tokushima journal of experimental medicine,
Wolfgang Seidel-Guyenot, and Ruth Alt, and Sylwia Perschon, and Jürgen Knop, and Kerstin Steinbrink
July 1996, European journal of immunology,
Wolfgang Seidel-Guyenot, and Ruth Alt, and Sylwia Perschon, and Jürgen Knop, and Kerstin Steinbrink
November 2009, The Journal of investigative dermatology,
Wolfgang Seidel-Guyenot, and Ruth Alt, and Sylwia Perschon, and Jürgen Knop, and Kerstin Steinbrink
May 2006, Nature immunology,
Wolfgang Seidel-Guyenot, and Ruth Alt, and Sylwia Perschon, and Jürgen Knop, and Kerstin Steinbrink
September 2000, Journal of dermatological science,
Copied contents to your clipboard!